Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds ...

A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

Rakuten Medical Inc.’s RM-0256 has been selected for funding by Japan’s Agency for Medical Research and Development (AMED).

Human adenovirus may cause severe infections in both immunosuppressed and immunocompetent individuals and there is no ...

The EMA has issued a new guideline on how to include and/or retain pregnant and breastfeeding women in clinical trials, in a ...

Researchers at ETH Zürich developed Menstruai, a device that detects in menstruation blood biomarkers associated with certain ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from ...

In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division ...

Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.